Zyversa Therapeutics Stock Investor Sentiment
| ZVSA Stock | 0.63 0.03 4.55% |
About 53% of ZyVersa Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding ZyVersa Therapeutics suggests that many traders are impartial. The current market sentiment, together with ZyVersa Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use ZyVersa Therapeutics stock news signals to limit their universe of possible portfolio assets.
Comfort Level 47
Impartial
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use ZyVersa Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward ZyVersa Therapeutics.
News SentimentBullish | Hype SentimentBearish | Insider SentimentWaiting |
ZyVersa Historical Sentiment
Although ZyVersa Therapeutics' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding ZyVersa, such as negative comments on social media and news outlets, may cause fear in the market and push ZyVersa Therapeutics' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of ZyVersa.
ZyVersa Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards ZyVersa Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
ZyVersa Therapeutics Historical Investor Sentiment
Investor biases related to ZyVersa Therapeutics' public news can be used to forecast risks associated with an investment in ZyVersa. The trend in average sentiment can be used to explain how an investor holding ZyVersa can time the market purely based on public headlines and social activities around ZyVersa Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
ZyVersa Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for ZyVersa Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average ZyVersa Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on ZyVersa Therapeutics.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of ZyVersa Therapeutics' Stock prices. Below is the latest headlines and news related to ZyVersa Therapeutics Stock. Current markets are slightly bearish. About 58% of major world exchanges and indexes are down. See today's market update for more information.
There is far too much social signal, news, headlines, and media speculation about ZyVersa Therapeutics that are available to investors today. This information is accessible both publicly - through ZyVersa Therapeutics' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of ZyVersa-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of ZyVersa Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of ZyVersa Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to ZyVersa Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive ZyVersa Therapeutics alpha.
ZyVersa Largest EPS Surprises
Earnings surprises can significantly impact ZyVersa Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-11-14 | 2023-09-30 | -0.16 | -0.09 | 0.07 | 43 | ||
2024-08-12 | 2024-06-30 | -3.75 | -3.31 | 0.44 | 11 | ||
2024-11-14 | 2024-09-30 | -1.6 | -2.43 | -0.83 | 51 | ||
2024-05-15 | 2024-03-31 | -3.7 | -4.53 | -0.83 | 22 | ||
2024-03-25 | 2023-12-31 | -2.14 | -13.68 | -11.54 | 539 |
There is far too much social signal, news, headlines, and media speculation about ZyVersa Therapeutics that are available to investors today. This information is accessible both publicly - through ZyVersa Therapeutics' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of ZyVersa-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of ZyVersa Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of ZyVersa Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to ZyVersa Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive ZyVersa Therapeutics alpha.
ZyVersa Therapeutics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Can ZyVersas Breakthrough Therapy Challenge Semaglutide in Obesity and Heart Failure - StockTitan | 03/05/2025 |
2 | Acquisition by Finizio Robert G of 132 shares of ZyVersa Therapeutics at 152.46 subject to Rule 16b-3 | 03/20/2025 |
3 | ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update | 03/27/2025 |
4 | ZyVersa Therapeutics Reports 2024 Financial Results and Pipeline Developments | 04/08/2025 |
5 | ZyVersa Advances Inflammasome ASC Inhibitor IC 100 for Inflammatory Diseases ZVSA ... | 04/24/2025 |
6 | ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Co... | 04/29/2025 |
7 | Acquisition by Karen Cashmere of 9927 shares of ZyVersa Therapeutics subject to Rule 16b-3 | 04/30/2025 |
8 | ZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 ... | 05/07/2025 |
9 | ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress | 05/12/2025 |
10 | ZVSA ZyVersa Therapeutics IC 100 Shows Promise in PD Treatment ZVSA Stock News | 05/20/2025 |
Complementary Tools for ZyVersa Stock analysis
When running ZyVersa Therapeutics' price analysis, check to measure ZyVersa Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ZyVersa Therapeutics is operating at the current time. Most of ZyVersa Therapeutics' value examination focuses on studying past and present price action to predict the probability of ZyVersa Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ZyVersa Therapeutics' price. Additionally, you may evaluate how the addition of ZyVersa Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |